C2 PHARMA Receives CEP approval for Naphazoline Nitrate

Cork, Ireland — April 23, 2026 – C2 PHARMA, the global leader in ophthalmic active pharmaceutical ingredients (APIs), is pleased to announce that the European Directorate for the Quality of Medicines & HealthCare (EDQM) has granted a Certificate of Suitability (CEP) for Naphazoline Nitrate.

This approval further strengthens our ophthalmic portfolio and expands market access alongside our existing international registrations across key global markets. Regulatory authorities in numerous regions, including Asia Pacific and other CEP-recognizing territories, may rely on the CEP within their approval pathways, supporting broader availability of this important API worldwide.

Naphazoline Nitrate is a well-established sympathomimetic agent widely used in ophthalmic formulations for the temporary relief of ocular redness and irritation through its vasoconstrictive action. Recognized for its effectiveness and long-standing use in eye care therapies, it remains an important ingredient in products designed to improve patient comfort and ocular wellness.

The inclusion of Naphazoline Nitrate reflects C2 PHARMA’s continued commitment to delivering reliable, high-quality solutions for essential eye care treatments. With one of the industry’s most comprehensive ophthalmic API portfolios,

C2 PHARMA continues to support partners worldwide through regulatory excellence, supply security, and specialized market expertise.